Telmisartan and Amlodipine Medication Recalled in U.S.

Patients taking this blood pressure medication should check their pill bottles for specific lot numbers affected by this recall.

Updated on Oct. 21, 2026 in Heart Disease

Isometric editorial illustration of a solitary, unlabeled amber pharmaceutical bottle on a flat surface, representing a product recall. — Vitaris Inc. has issued a voluntary recall for 21,600 bottles of telmisartan and amlodipine tablets due to a superpotency issue. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical companies maintain consistent quality standards for the medications you use?

Vitaris Inc. has recalled 21,600 bottles of telmisartan and amlodipine tablets due to a superpotency issue involving the telmisartan content. This voluntary recall affects specific lots of the blood pressure medication currently distributed within the United States.

Why it matters

A recall for superpotency means the medication contains a higher concentration of the active ingredient than specified, which can impact blood pressure management. The FDA classified this as a Class III recall, indicating the product is unlikely to cause adverse health consequences.

The FDA initiated this Class III recall involving 21,600 bottles after discovering the telmisartan levels exceeded prescribed specifications in specific lots. The exact margin by which the medication deviates from its intended potency remains under investigation.

The players

Vitaris Inc.

The pharmaceutical company that initiated the voluntary recall of its blood pressure medication.

Mylan Pharmaceuticals, Inc.

The pharmaceutical firm that markets and distributes the telmisartan and amlodipine tablets.

FDA

The federal agency responsible for overseeing drug safety and classifying pharmaceutical recalls.

The details

The affected medication consists of 40-milligram doses of telmisartan and 5-milligram doses of amlodipine in 30-count bottles. Superpotency occurs when a drug contains more of an active ingredient than allowed by quality standards, which can potentially lead to stronger than intended physiological effects. Vitaris Inc. manufactured these tablets in India for Mylan Pharmaceuticals, Inc. to be distributed to patients in the United States.

Vitaris Inc. initiated the recall of the medication on October 1, 2026.
The FDA posted the official recall notice during the week of October 21, 2026.
Lots 3228113, 3228114, and 3228115 have an expiration date of October 31, 2026.
Lots 3228120 and 3228121 have an expiration date of November 30, 2026.

Health Landscape

This action aligns with the FDA's Class III recall classification system, which serves as a regulatory standard for identifying products unlikely to cause significant health risks. It follows broader pharmaceutical industry trends in monitoring manufacturing specifications for exported medications.

Patients currently taking telmisartan and amlodipine should check their medication bottles for lot numbers 3228113, 3228114, 3228115, 3228120, or 3228121. If you find a matching lot number, it is worth discussing the recall with your physician or pharmacist regarding the next steps for your treatment plan.

The takeaway

While this recall is a Class III event, it serves as a reminder for patients to regularly check their medication packaging for manufacturing updates. If you have concerns about your current prescription, contact your pharmacist to verify your lot number against the latest safety notifications.